EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients (EVEREST)

A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients

Primary Objective

-To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell

Secondary Objectives

• To evaluate the efficacy of dupilumab in improving chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms at Week 24 compared to omalizumab
• To evaluate the efficacy of dupilumab in improving CRSwNP total symptom score (TSS) at Week 24 compared to omalizumab
• To evaluate the effect of dupilumab on health related quality of life (HRQoL) at week 24 compared to omalizumab
• To evaluate the efficacy of dupilumab in improving nasal peak inspiratory flow at Week 24 compared to omalizumab
• To evaluate the effect of dupilumab on CRSwNP overall disease severity at Week 24 compared to omalizumab
• To evaluate the safety of dupilumab and omalizumab

Study Overview

• Status: Completed
• Conditions: Asthma; Chronic Rhinosinusitis With Nasal Polyps
• Intervention / Treatment: Drug: Dupilumab; Drug: Placebo; Drug: Omalizumab

Detailed Description

Study duration per participant will be 38 weeks. The study will comprise 3 periods: 28 days ± 3 days screening and run-in period; 24 weeks Randomized investigational medicinal product (IMP) intervention period; up to 12 weeks follow-up period.

• Study Type: Interventional
• Enrollment (Actual): 360
• Phase: Phase 4

Contacts and Locations

Study Locations

• Belgium
  • Ghent, Belgium, 9000
    • Investigational Site Number : 0560001
  • Leuven, Belgium, 3000
    • Investigational Site Number : 0560002
  • Woluwe-Saint-Lambert, Belgium, 1200
    • Investigational Site Number : 0560003
• Canada
  • Québec, Canada, G1V 4G5
    • Investigational Site Number : 1240003
  • Ontario
    • London, Ontario, Canada, N6A 5A5
      • Investigational Site Number : 1240004
  • Quebec
    • Montreal, Quebec, Canada, H4a 3j1
      • Investigational Site Number : 1240002
• Czechia
  • Benešov, Czechia, 256 01
    • Investigational Site Number : 2030007
  • Hradec Králové, Czechia, 50005
    • Investigational Site Number : 2030001
  • Ostrava - Poruba, Czechia, 70852
    • Investigational Site Number : 2030003
  • Pardubice, Czechia, 53203
    • Investigational Site Number : 2030002
  • Pilsen, Czechia, 30599
    • Investigational Site Number : 2030012
  • Prague, Czechia, 10034
    • Investigational Site Number : 2030010
  • Prague, Czechia, 12808
    • Investigational Site Number : 2030006
  • Prague, Czechia, 14059
    • Investigational Site Number : 2030008
  • Praha 5 - Motole, Czechia, 15006
    • Investigational Site Number : 2030004
• Denmark
  • Aarhus, Denmark, 8200
    • Investigational Site Number : 2080003
  • Copenhagen, Denmark, 2100
    • Investigational Site Number : 2080001
• Finland
  • Helsinki, Finland, 00029 HUS
    • Investigational Site Number : 2460003
  • Tampere, Finland, 33520
    • Investigational Site Number : 2460002
• France
  • Créteil, France, 94010
    • Investigational Site Number : 2500009
  • La Roche-sur-Yon, France, 85925
    • Investigational Site Number : 2500006
  • Le Kremlin-Bicêtre, France, 94275
    • Investigational Site Number : 2500008
  • Lille, France, 59037
    • Investigational Site Number : 2500002
  • Marseille, France, 13005
    • Investigational Site Number : 2500004
  • Montpellier, France, 34295
    • Investigational Site Number : 2500005
  • Toulouse, France, 31059
    • Investigational Site Number : 2500007
• Germany
  • Berlin, Germany, 13353
    • Investigational Site Number : 2760002
  • Düsseldorf, Germany, 40225
    • Investigational Site Number : 2760004
  • München, Germany, 81377
    • Investigational Site Number : 2760003
  • Münster, Germany, 48149
    • Investigational Site Number : 2760001
• Hungary
  • Budapest, Hungary, 1115
    • Investigational Site Number : 3480004
  • Budapest, Hungary, 1083
    • Investigational Site Number : 3480007
  • Debrecen, Hungary, 4026
    • Investigational Site Number : 3480005
  • Edelény, Hungary, 3780
    • Investigational Site Number : 3480006
  • Pécs, Hungary, 7621
    • Investigational Site Number : 3480002
  • Szeged, Hungary, 6725
    • Investigational Site Number : 3480001
• Italy
  • Catania, Italy, 95123
    • Investigational Site Number : 3800003
  • Florence, Italy, 50134
    • Investigational Site Number : 3800004
  • Milan, Italy, 20132
    • Investigational Site Number : 3800006
  • Varese, Italy, 21100
    • Investigational Site Number : 3800005
  • Lazio
    • Rome, Lazio, Italy, 00168
      • Investigational Site Number : 3800002
  • Lombardy
    • Rozzano, Lombardy, Italy, 20089
      • Investigational Site Number : 3800001
• Mexico
  • Chihuahua City, Mexico, 31000
    • Investigational Site Number : 4840002
  • Durango, Mexico, 34000
    • Investigational Site Number : 4840004
  • Jalisco
    • Guadalajara, Jalisco, Mexico, 44100
      • Investigational Site Number : 4840003
• Poland
  • Krakow, Poland, 30-033
    • Investigational Site Number : 6160001
  • Lodz, Poland, 90141
    • Investigational Site Number : 6160007
  • Środa Wielkopolska, Poland, 63000
    • Investigational Site Number : 6160006
  • Greater Poland Voivodeship
    • Poznan, Greater Poland Voivodeship, Poland, 60-693
      • Investigational Site Number : 6160004
  • Masovian Voivodeship
    • Warsaw, Masovian Voivodeship, Poland, 04-141
      • Investigational Site Number : 6160008
  • Silesian Voivodeship
    • Katowice, Silesian Voivodeship, Poland, 40-611
      • Investigational Site Number : 6160005
• Portugal
  • Almada, Portugal, 2801-951
    • Investigational Site Number : 6200005
  • Aveiro, Portugal, 3814-501
    • Investigational Site Number : 6200003
  • Guimarães, Portugal, 4810-061
    • Investigational Site Number : 6200006
  • Matosinhos Municipality, Portugal, 4454-509
    • Investigational Site Number : 6200001
  • Santa Maria da Feira, Portugal, 4520-211
    • Investigational Site Number : 6200007
• Romania
  • Brasov, Romania, 500283
    • Investigational Site Number : 6420002
  • Craiova, Romania, 200222
    • Investigational Site Number : 6420004
• Spain
  • Andalusia
    • Seville, Andalusia, Spain, 41009
      • Investigational Site Number : 7240001
  • Barcelona [Barcelona]
    • Barcelona, Barcelona [Barcelona], Spain, 08036
      • Investigational Site Number : 7240005
    • L'Hospitalet de Llobregat, Barcelona [Barcelona], Spain, 08907
      • Investigational Site Number : 7240008
  • Cádiz
    • Jerez de la Frontera, Cádiz, Spain, 11407
      • Investigational Site Number : 7240003
  • Madrid
    • Majadahonda, Madrid, Spain, 28222
      • Investigational Site Number : 7240007
  • Madrid, Comunidad de
    • Madrid / Madrid, Madrid, Comunidad de, Spain, 28040
      • Investigational Site Number : 7240004
  • Navarre
    • Pamplona, Navarre, Spain, 31080
      • Investigational Site Number : 7240006
• Sweden
  • Gothenburg, Sweden, 413 45
    • Investigational Site Number : 7520003
  • Lund, Sweden, 221 85
    • Investigational Site Number : 7520002
  • Stockholm, Sweden, 171 76
    • Investigational Site Number : 7520001
• United Kingdom
  • Manchester, United Kingdom, M23 9LT
    • Investigational Site Number : 8260002
  • Newcastle upon Tyne, United Kingdom, NE7 7DN
    • Investigational Site Number : 8260001
  • Lancashire
    • Wigan, Lancashire, United Kingdom, WN6 9EP
      • Investigational Site Number : 8260003
• United States
  • California
    • Los Angeles, California, United States, 90048
      • Cedars Sinai Medical Center Site Number : 8400026
  • Florida
    • Tampa, Florida, United States, 33613
      • Asthma Allergy & Immunology Clinical Research Unit Site Number : 8400027
  • Illinois
    • Chicago, Illinois, United States, 60612
      • University of Illinois
    • Chicago, Illinois, United States, 60611
      • Northwestern University Site Number : 8400001
  • Kentucky
    • Louisville, Kentucky, United States, 40220
      • Advanced ENT and Allergy Site Number : 8400013
  • Missouri
    • Columbia, Missouri, United States, 65212
      • University of Missouri Health Care - University Hospital Site Number : 8400016
  • New York
    • Great Neck, New York, United States, 11021
      • Northwell Health Site Number : 8400044
    • Rochester, New York, United States, 14642
      • University of Rochester Site Number : 8400015
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic Foundation Site Number : 8400029
    • Columbus, Ohio, United States, 43235
      • Optimed Research, LTD Site Number : 8400014
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73120
      • Allergy, Asthma and Clinical Research Center Site Number : 8400037
    • Tulsa, Oklahoma, United States, 74137
      • Essential Medical Research, LLC Site Number : 8400024
  • Oregon
    • Portland, Oregon, United States, 97239
      • Oregon Health & Science University Site Number : 8400031
  • Texas
    • Houston, Texas, United States, 77030
      • University of Texas Health Science Center- Site Number : 8400019
  • Utah
    • St. George, Utah, United States, 84790
      • Chryaslis Clinical Research Site Number : 8400017
  • Virginia
    • Norfolk, Virginia, United States, 23507
      • Eastern Virginia Medical School Site Number : 8400010

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participant must be at least 18 (or the legal age of consent in the jurisdiction in which the study is taking place) years of age inclusive, at the time of signing the informed consent.

• Participants with bilateral sino-nasal polyposis, that despite prior treatment with Systemic corticosteroids (SCS) anytime within the past 2 years; and/or medical contraindication/intolerance to SCS; and/or prior surgery for NP have:

  • An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity) at visit 1; AND
  • Ongoing symptoms of Nasal congestion/blockade/obstruction and loss of smell for at least 8 weeks before screening (Visit 1), AND
  • Nasal congestion/blockade/obstruction and a weekly average severity greater than 1 in the 7 days before randomization (Visit 2) AND
  • loss of smell symptom severity score 2 or 3 at screening (Visit 1) and a weekly average severity of greater than 1 in the 7 days before randomization (Visit 2).
• Participants with a physician diagnosis of asthma based on the Global Initiative for Asthma (GINA) 2020 treated with low, medium or high dose inhaled corticosteroids (ICS) and a second controller (ie, LABA), a third controller is allowed but not mandatory. The dose regimen was to be stable for at least 1 month before Visit 1 (screening visit) and during the screening and run-in period.
• Asthma Control Questionnaire 5-question version (ACQ-5) score ≥1.5 at Visits 1 or 2.
• Treatment with intranasal mometasone ≥200 μg once daily (QD) (or equivalent of another INCS) for 1 month prior to Visit 1 and during the run-in period (for CRSwNP).
• Eligibility as per omalizumab drug-dosing table (serum IgE level ≥30 to ≤1500 IU/mL and body weight ≥30 to ≤150 kg) and ability to be dosed per the dosing table.

Exclusion Criteria:

Participants were excluded from the study if any of the following criteria apply:

• Participants who underwent any sinus intranasal surgery (including polypectomy) within 6 months before Visit 1.
• Participants who had a sino-nasal surgery changing the lateral wall structure of the nose, making impossible the evaluation of NPS.
• Participants with conditions/concomitant diseases making them non evaluable at Visit 1 or for the primary efficacy endpoint such as: Antrochoanal polyps, Nasal septal deviation that would occlude at least one nostril, Acute sinusitis, nasal infection, or upper respiratory infection.
• Severe asthma exacerbation requiring treatment with SCS in the last 4 weeks prior to Visit 1 and during screening.
• Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study
• Diagnosed with, suspected of, or at high risk of endoparasitic infection, and/or use of antiparasitic drugs within 2 weeks before Visit 1 (screening visit) or during the screening and run-in period.
• History of human immunodeficiency virus (HIV) infection or positive HIV 1/2 serology at Visit 1 (screening visit).
• Known or suspected immunodeficiency, including history of invasive opportunistic infections
• Active malignancy or history of malignancy within 5 years before Visit 1 (screening visit), except completely treated in situ carcinoma of the cervix and completely treated and resolved non metastatic squamous or basal cell carcinoma of the skin.
• History of systemic hypersensitivity or anaphylaxis to dupilumab and omalizumab, including any excipient
• Treatment with a live (attenuated) vaccine within 4 weeks before Visit 1 (screening visit).

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dupilumab 300 mg Q2W; Participants received dupilumab 300 milligrams (mg) subcutaneous (SC) injection every 2 weeks (Q2W) for 24 weeks.	Drug: Dupilumab; solution for injection subcutaneous; Other Names: SAR231893 Dupixent; Drug: Placebo; solution for injection subcutaneous
Experimental: Omalizumab 75 to 600 mg Q2W/Q4W; Participants received omalizumab 75 to 600 mg SC injection Q2W/every 4 weeks (Q4W) based on their serum immunoglobulin E (IgE) levels and body weight for 24 weeks.	Drug: Placebo; solution for injection subcutaneous; Drug: Omalizumab; solution for injection subcutaneous; Other Names: Xolair

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline to Week 24 in Nasal Polyp Score	The NPS was assessed by the independent physician to grade the extent/severity of nasal polyps based on evaluation by nasal endoscopy. The NPS scores for each nostril was graded based on polyp size from 0 (no polyps) to 4 (large polyps causing complete obstruction of the inferior nasal cavity). The total NPS score was calculated as the sum of right and left nostril scores and ranged from 0 (no polyps) to 8 (large polyps). Higher scores indicated more extensive or severe nasal polyps. Negative change from baseline indicated less severity of nasal polyps. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.	Baseline (Day 1) and Week 24
Change From Baseline to Week 24 in University of Pennsylvania Smell Identification Test	The UPSIT was a 40-item test to quantitatively assess human olfactory function. The UPSIT test consisted of 4 booklets, each containing 10 odorants with 1 odorant per page. The participant was asked to release the odorant by rubbing the brown-strip (contained odorant microcapsules) with the tip of a pencil and to indicate which of 4 words best described the odor. Thus, each participant received a score out of 40 possible correct answers. The total UPSIT score ranged from 0 (loss of smell/anosmia) to 40 (normal sense of smell/normosmia). Higher scores indicated better olfactory function. Positive change from baseline indicated normal olfactory function. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.	Baseline (Day 1) and Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline to Week 24 in the Loss of Smell Score of the Chronic Rhinosinusitis With Nasal Polyp (CRSwNP) Nasal Symptom Diary	The nasal symptom diary was designed to assess the severity of chronic rhinosinusitis nasal symptoms daily. These symptoms included nasal congestion (NC)/obstruction, loss of smell, anterior rhinorrhea, and posterior rhinorrhea. The severity of loss of smell was scored by participants using a scale ranged from 0 to 3 (where, 0= no symptoms, 1= mild symptoms, 2= moderate symptoms and 3= severe symptoms that were hard to tolerate, caused interference with activities, or daily living). Higher scores indicated greater symptom severity. Negative change from baseline indicated less severe symptom. Baseline value was calculated by averaging the data collected/recorded from Day -6 to Day 1.	Baseline (average of Day -6 to Day 1) and Week 24
Change From Baseline to Week 24 in the Nasal Congestion Score of the Chronic Rhinosinusitis With Nasal Polyp Nasal Symptom Diary	The nasal symptom diary was designed to assess the severity of chronic rhinosinusitis nasal symptoms daily. These symptoms included NC/obstruction, loss of smell, anterior rhinorrhea, and posterior rhinorrhea. The severity of NC was scored by participants using a scale ranged from 0 to 3 (where, 0= no symptoms, 1= mild symptoms, 2= moderate symptoms and 3= severe symptoms that were hard to tolerate, caused interference with activities, or daily living). Higher scores indicated greater symptom severity. Negative change from baseline indicated less severe symptom. Baseline value was calculated by averaging the data collected/recorded from Day -6 to Day 1.	Baseline (average of Day -6 to Day 1) and Week 24
Change From Baseline to Week 24 in Total Symptom Score (TSS) Derived From the Chronic Rhinosinusitis With Nasal Polyp Nasal Symptom Diary	The TSS is a composite score consisted of the following symptoms assessed daily in the morning: NC/obstruction, decreased/loss of sense of smell, and rhinorrhea (average of anterior/posterior nasal discharge). Each item was scored on a scale ranged from 0 to 3 (where, 0= no symptoms, 1= mild symptoms, 2= moderate symptoms and 3= severe symptoms that were hard to tolerate, and caused interference with activities, or daily living). Higher score indicated greater symptom severity. The TSS score was calculated by summing the individual symptom score and ranged from 0 (no symptoms) to 9 (severe symptoms). Higher scores on the TSS indicated greater symptom severity. Negative change from baseline indicated less severe symptom. Baseline was calculated by averaging the data collected/recorded from Day -6 to Day 1.	Baseline (average of Day -6 to Day 1) and Week 24
Change From Baseline to Week 24 in Sino-Nasal Outcome Test 22-Items (SNOT-22) Total Score	The SNOT-22 is a patient-reported outcome questionnaire designed to assess the impact of chronic rhinosinusitis on participants' health-related quality of life. The SNOT-22 consisted of 22 items covering symptoms, social/emotional impact, productivity, and sleep consequences of chronic rhinosinusitis. Each item was rated on a 6-point Likert scale response option, score ranged from 0 (no problem) to 5 (problem as bad as it can be). The SNOT-22 total score was the sum of each item score, and it ranged from 0 (no problem) to 110 (problem as bad as it can be). Higher scores indicated greater rhinosinusitis-related health burden, meaning for this parameter lower score indicated better condition. Negative change from baseline indicated improvement in health-related quality of life. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.	Baseline (Day 1) and Week 24
Change From Baseline to Week 24 in Sino-Nasal Outcome Test 22-Items: Nasal Domain Score	SNOT-22 is a patient-reported outcome questionnaire designed to assess impact of chronic rhinosinusitis on participants' health-related quality of life. SNOT-22 was categorized into 5 domains: Nasal (items 1, 2, 3, 4, 5, 6, 7 and 12); Ear/Facial (items 8, 9, 10 and 11); Sleep (items 13, 14, 15 and 16); Function (items 17, 18 and 19); Emotion (items 20, 21 and 22). Each item of Nasal domain was rated on a 6-point Likert scale ranged from 0 (no problem) to 5 (problem as bad as it can be) with higher score indicated greater rhinosinusitis-related health burden. Total score of Nasal domain was average score of items of nasal domain, and ranged from 0 (no problem) to 5 (problem as bad as it can be), where higher score indicated greater rhinosinusitis-related health burden. Negative change from baseline indicated improvement in health-related quality of life. Baseline was defined as last available valid (non-missing) value up to and including day of first administration of study treatment.	Baseline (Day 1) and Week 24
Change From Baseline to Week 24 in Nasal Peak Inspiratory Flow (NPIF)	The NPIF evaluation represented a physiologic measure of the air flow through both nasal cavities during forced inspiration. The NPIF is the best validated technique for the evaluation of nasal flow through the nose. Participants were issued an NPIF meter and were instructed on the use of the device and written instructions on the use of the NPIF meter was provided. Higher NPIF values were indicative of better nasal air flow. Positive change from baseline indicated better nasal air flow. Baseline was the mean measurement recorded for the 7 days (Day -6 to Day 1) prior to first dose of study treatment.	Baseline (average of Day -6 to Day 1) and Week 24
Change From Baseline to Week 24 in Rhinosinusitis Visual Analogue Scale (Rhinosinusitis VAS)	The rhinosinusitis severity VAS was used to evaluate the overall severity of the rhinosinusitis. It is a recommended scale to determine the participant's disease severity and to guide the treatment for chronic rhinosinusitis. The participants were asked to answer the following question: "How troublesome are your symptoms of your rhinosinusitis" on a 10-centimeter VAS from 0 (not troublesome) to 10 (worst thinkable troublesome). Higher scores on the VAS score indicated more severe chronic rhinosinusitis. Negative change from baseline indicated less severity of rhinosinusitis. Baseline was defined as the last available valid (non-missing) value up to and including the day of first administration of study treatment.	Baseline (Day 1) and Week 24
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events of Special Interest (AESIs)	An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. The TEAEs was defined as an AEs that occurred from the first administration of the study treatment (on Day 1) up to 98 days after the last dose of study treatment administration.	From first dose of study treatment administration (Day 1) up to 98 days after the last dose of study treatment administration (considering the maximum duration of treatment exposure) i.e., up to approximately 329 days

Collaborators and Investigators

• Sponsor: Sanofi
• Collaborators: Regeneron Pharmaceuticals

Publications and helpful links

General Publications

• De Prado Gomez PharmD MSc L, Khan Mbbs Mph AH, Peters Md AT, Bachert Md PhD C, Wagenmann Md M, Heffler Md PhD E, Hopkins BMBCh C, Hellings Md PhD PW, Zhang PhD M, Xing PhD J, Rowe Md P, Jacob-Nara Md Mph DHSc JA. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design. Am J Rhinol Allergy. 2022 Nov;36(6):788-795. doi: 10.1177/19458924221112211. Epub 2022 Jul 15.
• De Corso E, Canonica GW, Heffler E, Springer M, Grzegorzek T, Viana M, Horvath Z, Mullol J, Gevaert P, Michel J, Peters AT, Wagenmann M, Zaghloul S, Zhang M, Corbett M, Nash S, Angello JT, Radwan A, Deniz Y, Martin A, Hellings PW. Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. Lancet Respir Med. 2025 Sep 28:S2213-2600(25)00287-5. doi: 10.1016/S2213-2600(25)00287-5. Online ahead of print.

Helpful Links

• LPS16747 Chronic Rhinosinusitis with Nasal Polyps Dupilumab Trial website
• LPS16747 Plain Language Results Summary

Study record dates

Study Major Dates

• Study Start (Actual): September 27, 2021
• Primary Completion (Actual): October 16, 2024
• Study Completion (Actual): December 27, 2024

Study Registration Dates

• First Submitted: August 9, 2021
• First Submitted That Met QC Criteria: August 9, 2021
• First Posted (Actual): August 10, 2021

Study Record Updates

• Last Update Posted (Estimated): October 23, 2025
• Last Update Submitted That Met QC Criteria: October 8, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Respiratory Tract Diseases; Lung Diseases; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Asthma; Amino Acids, Peptides, and Proteins; Proteins; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Serum Globulins; Globulins; Antibodies, Anti-Idiotypic; Omalizumab; dupilumab
• Other Study ID Numbers: LPS16747 (Sanofi Identifier); 2021-000829-27 (EudraCT Number); U1111-1255-4713 (Registry Identifier: ICTRP)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes